Health News

Treating Refractory Hematological Malignancies - Multiple Myeloma (MM): New Treatment Options Driving In-Licensing and M A

Author: Australian Business

NEW YORK, Oct. 2, 2013 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue: Treating Refractory Hematological Malignancies – Multiple Myeloma (MM): New Treatment Options Driving In-Licensing and......

More...

More Articles...

An Anti-Aging Alliance Emerges within the Skincare Industry
Nederländska psykiatriska sjukvårdsgivare använder Ekahaus realtidslokaliseringssystem och Ascom-telefoner för att garantera personalens säkerhet
Innovative Brands Remain Robust within Kenya's Private Pharmaceutical Market
AtheroMed Announces Completion of Patient Enrollment in the EASE Study Evaluating the Phoenix Atherectomy System in Treating PAD
LCA-Vision Reports 4% Increase in Third Quarter 2013 Procedures
Ambit Announces Participation At 12th Annual BIO Investor Forum
PDL BioPharma Provides $60 Million in Financing to LENSAR
US and European Regulators Accept for Review OMS302 Marketing Applications
El NHS de Inglaterra designa a SIRT (radioterapia interna selectiva) como el primer tratamiento disponible a través de la nueva iniciativa "Commissioning through Evaluation"
Expatriates Could be Paying Too Much For International Private Medical Insurance

Page 1257 of 1908